Company: CERO
Filing Date: 2025-06-06
Form Type: 8-K
Source: 0001213900-25-051750
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-06-06
Form: 8-K
Item: Item 3.02
Chunk 0
---
Item 3.02      Unregistered Sales of Equity Securities.  

As previously reported on the Current Report on Form
8-K filed with the Securities and Exchange Commission (the “ SEC”) on April 22, 2025, CERo Therapeutics Holdings, Inc. (the
“ Company”) entered into a securities purchase agreement (the “ Securities Purchase Agreement”) with certain institutional
investors (the “ Investors”), pursuant to which the Company agreed to issue and sell, in one or more closings, up to 10,000
shares of the Company’s Series D convertible preferred stock, par value $0.0001 per share (the “ Series D Preferred Stock”),
which are convertible into shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock”), in
a private placement offering.

On June 5, 2025, pursuant to the Securities Purchase
Agreement, the Company and certain Investors, mutually agreed to effect, and effected, an Additional Closing (as defined in the Securities
Purchase Agreement), with respect to 938 additional shares of Series D Preferred Stock for gross proceeds of approximately $750,400. The
rights, preferences and privileges of the Series D Preferred Stock are set forth in the certificate of designations of rights and preferences
of the Series D Preferred Stock (the “ Certificate of Designations”), filed with the Secretary of State of the State of Delaware
on April 22, 2025. The offering and sale of the shares of Series D Preferred Stock were issued and, upon conversion of the Series D Preferred
Stock, the shares of Common Stock underlying the Series D Preferred Stock will be issued, in each case, without registration under the
Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “ Securities
Act”) as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited
investors, and in reliance on similar exemptions under applicable state laws.

The description of the terms and conditions of the
Securities Purchase Agreement and the Certificate of Designations do not purport to be complete and each is qualified in its entirety
by the full text of Securities Purchase Agreement and the Certificate of Designations, as applicable, which are filed as exhibits to the
Company’s Current Reports on Form 8-K filed on April 22, 2025 and on April 25,